Skip to content

Mylan and Biocon launch Semglee in U.S.

August 31, 2020

Mylan N.V. (NASDAQ:MYL) and Biocon Biologics India, a subsidiary of Biocon Ltd. (OTC:BCNQY), announce the U.S. launch of Semglee (insulin glargine injection) in vial and pre-filled pen to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not recommended for the treatment of diabetic ketoacidosis.

FDA approved Semglee has an identical amino acid sequence to Sanofi’s Lantus.

Mylan is offering Semglee at a wholesale acquisition cost (WAC) of $147.98/package of five 3ml pens and $98.65 per 10ml vial, representing the lowest WAC for any long-acting insulin glargine on the market.

Additionally, Mylan has submitted to the FDA all necessary documentation to request approval of Semglee as a biosimilar to Lantus under the 351(k) pathway and remains confident in seeking an interchangeability designation.

Sanofi’s total IQVIA sales for the 12 months ending June 30 were ~$1.64B for Lantus 100 Units/mL Vial and ~$4.36B for Lantus SoloSTAR Pen.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: